He JC, WuY, Wang YD. The independent association between age and serum cholesterol levels in patients with familial hypercholesterolemia. Discov Med. 2022;34(173):171–80.

PubMed  Google Scholar 

Slivnick J, Lampert BC. Hypertension and heart failure. Heart Fail Clin. 2019;15(4):531–41.

Article  PubMed  Google Scholar 

Di Palo KE, Barone NJ. Hypertension and heart failure: prevention, targets, and treatment. Cardiol Clin. 2022;40(2):237–44.

Article  PubMed  Google Scholar 

Jackson AM, Jhund PS, Anand IS, Düngen HD, Lam CSP, Lefkowitz MP, Linssen G, Lund LH, Maggioni AP, Pfeffer MA, Rouleau JL, Saraiva JFK, Senni M, Vardeny O, Wijkman MO, Yilmaz MB, Saito Y, Zile MR, Solomon SD, McMurray JJV. Sacubitril-Valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Eur Heart J. 2021;42(36):3741–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maron BA, Kovacs G, Vaidya A, Bhatt DL, Nishimura RA, Mak S, Guazzi M, Tedford RJ. Cardiopulmonary hemodynamics in pulmonary hypertension and heart failure: JACC review topic of the week. J Am Coll Cardiol. 2020;76(22):2671–81.

Article  PubMed  PubMed Central  Google Scholar 

Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, PonikowskiP, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O’Connor CM, VICTORIA Study Group. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382(20):1883–93.

Article  CAS  PubMed  Google Scholar 

Aimo A, Pateras K, Stamatelopoulos K, Bayes-Genis A, Lombardi CM, Passino C, Emdin M, Georgiopoulos G. Relative efficacy of sacubitril-valsartan, vericiguat, and SGLT2 inhibitors in heart failure with reduced ejection fraction: a systematic review and network meta-analysis. Cardiovasc Drugs Ther. 2021;35(5):1067–76.

Article  CAS  PubMed  Google Scholar 

Butler J, Zheng Y, Khan MS, Bonderman D, Lund LH, deFilippi CR, Blaustein RO, Ezekowitz JA, Freitas C, Hernandez AF, O’Connor CM, Voors AA, Westerhout CM, Lam CSP, Armstrong PW, VICTORIA Study Group. Ejection fraction, biomarkers, and outcomes and impact of vericiguat on outcomes across EF in VICTORIA. JACC Heart Fail. 2023;11(5):583–92.

Article  PubMed  Google Scholar 

Lombardi CM, Cimino G, Pagnesi M, Dell’Aquila A, Tomasoni D, Ravera A, Inciardi R, Carubelli V, Vizzardi E, Nodari S, Emdin M, Aimo A. Vericiguat for heart failure with reduced ejection fraction. CurrCardiol Rep. 2021;23(10):144.

Article  Google Scholar 

Yao ML, Liu J, Pan BY, Yu HT, Bao N. Prevention and treatment of fluid overload in bipolar hysteroscopy. J Biol Regulat Homeost Agent. 2022;36(3):437–44.

CAS  Google Scholar 

Eschen O, Christensen JH, Rovere LA, Romano MT, Sala P, Schmidt P. Effects of marine n-3 fatty acids on circulating levels of soluble adhesion molecules in patients with chronic heart failure. Cell Mol Biol (Noisy-le-grand). 2010;56(1):45–51.

CAS  PubMed  Google Scholar 

Vulesevic B, Lavoie SS, Neagoe PE, Dumas E, Räkel A, White M, Sirois MG. CRP induces NETosis in heart failure patients with or without diabetes. Immunohorizons. 2019;3(8):378–88.

Article  CAS  PubMed  Google Scholar 

Wang Q, An Y, Wang H, Zhang N, Deng S. The clinical significance of changes in cTnT, CRP and NT-proBNP levels in patients with heart failure. Am J Transl Res. 2021;13(4):2947–54.

PubMed  PubMed Central  Google Scholar 

Kumase F, Morizane Y, Mohri S, Takasu I, Ohtsuka A, Ohtsuki H. Glycocalyx degradation in retinal and choroidal capillary endothelium in rats with diabetes and hypertension. Acta Med Okayama. 2010;64(5):277–83.

PubMed  Google Scholar 

Savarese G, Stolfo D, Sinagra G, Lund LH. Heart failure with mid-range or mildly reduced ejection fraction. Nat Rev Cardiol. 2022;19(2):100–16.

Article  PubMed  Google Scholar 

Latic N, Erben RG. Vitamin D and cardiovascular disease, with emphasis on hypertension, atherosclerosis, and heart failure. Int J Mol Sci. 2020;21(18):6483.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hao G, Wang X, Chen Z, Zhang L, Zhang Y, Wei B, Zheng C, Kang Y, Jiang L, Zhu Z, Zhang J, Wang Z, Gao R. China Hypertension Survey investigators. Prevalence of heart failure and left ventricular dysfunction in China: China Hypertension Survey, 2012–2015. Eur J Heart Fail. 2019;21(11):1329–37.

Article  PubMed  Google Scholar 

Hicklin HE, Gilbert ON, Ye F, Brooks JE, Upadhya B. Hypertension as a road to treatment of heart failure with preserved ejection fraction. Curr Hypertens Rep. 2020;22(10):82.

Article  PubMed  Google Scholar 

Lam CSP, Giczewska A, Sliwa K, Edelmann F, Refsgaard J, Bocchi E, Ezekowitz JA, Hernandez AF, O’Connor CM, Roessig L, Patel MJ, Pieske B, Anstrom KJ, Armstrong PW, VICTORIA Study Group. Clinical outcomes and response to vericiguat according to index heart failure event: insights from the VICTORIA trial. JAMA Cardiol. 2021;6(6):706–12.

Article  PubMed  Google Scholar 

González-Juanatey JR, Anguita-Sánchez M, Bayes-Genís A, Comín-Colet J, García-Quintana A, Recio-Mayoral A, Zamorano-Gómez JL, Cepeda-Rodrigo JM, Manzano L. Vericiguat in heart failure: from scientific evidence to clinical practice. Rev Clin Esp (Barc). 2022;222(6):359–69.

Article  PubMed  Google Scholar 

Kassis-George H, Verlinden NJ, Fu S, Kanwar M. Vericiguat in heart failure with a reduced ejection fraction: patient selection and special considerations. Ther Clin Risk Manag. 2022;18:315–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Giannitsi S, Bougiakli M, Bechlioulis A, Kotsia A, Michalis LK, Naka KK. 6-minute walking test: a useful tool in the management of heart failure patients. TherAdvCardiovasc Dis. 2019;13:1753944719870084.

Google Scholar 

Kario K, Williams B. Nocturnal hypertension and heart failure: mechanisms, evidence, and new treatments. Hypertension. 2021;78(3):564–77.

Article  CAS  PubMed  Google Scholar 

Castagna F, McDonnell BJ, Mondellini GM, Gaudig A, Pinsino A, McEniery C, Stöhr EJ, Takeda K, Naka Y, Uriel N, Yuzefpolskaya M, Cockcroft J, Parati G, Colombo PC. Twenty-four-hour blood pressure and heart rate variability are reduced in patients on left ventricular assist device support. J Heart Lung Transpl. 2022;41(6):802–9.

Article  Google Scholar 

Liang L, Huang L, Zhao X, Zhao L, Tian P, Huang B, Feng J, Zhang J, Zhang Y. Prognostic value of RDW alone and in combination with NT-proBNP in patients with heart failure. ClinCardiol. 2022;45(7):802–13.

Google Scholar 

Sweeney C, Pharithi RB, Kerr B, Ryan C, Ryan F, Collins L, Halley C, Barrett M, Watson CJ, McDonald K, Ledwidge M. NT-proBNP/BNP ratio for prognostication in European caucasian patients enrolled in a heart failure prevention programme. ESC Heart Fail. 2021;8(6):5081–91.

Article  PubMed  PubMed Central  Google Scholar 

Yang X, Xing Y, Li K. Changes in clinical biochemical indexes of patients with heart failure with preserved ejection fraction or patients with hypertensive heart disease before and after treadmill exercise. Ann Palliat Med. 2021;10(7):7970–6.

Article  PubMed  Google Scholar 

Smeijer JD, Koomen J, Kohan DE, McMurray JJV, Bakris GL, Correa-Rotter R, Hou FF, JanuzziJL, Kitzman DW, Kolansky DM, Makino H, Perkovic V, Tobe S, Parving HH, de Zeeuw D, Heerspink HJL. Increase in BNP in response to endothelin-receptor antagonist atrasentan is associated with incidentheartfailure. JACC Heart Fail. 2022;10(7):498–507.

Article  PubMed  Google Scholar 

Miyauchi T, Sakai S. Endothelin and the heart in health and diseases. Peptides. 2019;111:77–88.

Article  CAS  PubMed  Google Scholar 

Indraratna P, Tardo D, Yu J, Delbaere K, Brodie M, Lovell N, Ooi SY. Mobile phone technologies in the management of ischemic heart disease, heart failure, and hypertension: systematic review and meta-analysis. JMIR MhealthUhealth. 2020;8(7):e16695.

Article  Google Scholar 

Pagel PS, Tawil JN, Boettcher BT, Izquierdo DA, Lazicki TJ, Crystal GJ, Freed JK. Heart failure with preserved ejection fraction: a comprehensive review and update of diagnosis, pathophysiology, treatment, and perioperative implications. J Cardiothorac Vasc Anesth. 2021;35(6):1839–59.

Article  PubMed  Google Scholar 

Fransén K, Pettersson C, Hurtig-Wennlöf A. CRP levels are significantly associated with CRP genotype and estrogen use in the lifestyle, biomarker and atherosclerosis (LBA) study. BMC Cardiovasc Disord. 2022;22(1):170.

Article  PubMed  PubMed Central  Google Scholar 

Selvaraj S, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Juliano RA, Jiao L, Tardif JC, Ballantyne CM, REDUCE-IT Investigators. Impact of icosapent ethyl on cardiovascular risk reduction in patients with heart failure in REDUCE-IT. J Am Heart Assoc. 2022;11(7):e024999.

Article  CAS  PubMed